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A B S T R A C T
Objective: Nonadherence to antipsychotic medication is highly prevalent in patients with schizophrenia
and has a deleterious impact on the course of the illness. This review seeks to determine the
interventions that were examined in the past decade to improve adherence rates.
Method: The literature between 2000 and 2009 was searched for randomized controlled trials which
compared a psychosocial intervention with another intervention or with treatment as usual in patients
with schizophrenia.
Results: Fifteen studies were identiﬁed, with a large heterogeneity in design, adherence measures and
outcome variables. Interventions that offered more sessions during a longer period of time, and
especially those with a continuous focus on adherence, seem most likely to be successful, as well as
pragmatic interventions that focus on attention and memory problems. The positive effects of adapted
forms of Motivational Interviewing found in earlier studies, such as compliance therapy, have not been
conﬁrmed.
Conclusion: Nonadherence remains a challenging problem in schizophrenia. The heterogeneity of factors
related to nonadherence calls for individually tailored approaches to promote adherence. More evidence
is required to determine the effects of speciﬁc interventions.
 2011 Elsevier Masson SAS. All rights reserved.1. Introduction
Antipsychotic medication is held to be the cornerstone in the
treatment of patients with schizophrenia. Antipsychotics are
effective in reducing psychotic symptoms, in preventing psychotic
relapses in maintenance therapy and in improving psychosocial
functioning [33]. Although some patients turn out to be treatment-
resistant to all antipsychotic medication, an effective antipsychotic
can be found among the available medications for the majority of
patients [15]. The overall efﬁcacy of antipsychotic medication in
comparative trials seems evident. However, the grim reality we
face is that the actual effectiveness of antipsychotics, for example
when we look at relapse rates in naturalistic studies, is much lower
than would be concluded from medication trials [62]. This efﬁcacy-
effectiveness gap may be largely due to adherence problems with
antipsychotic treatment [22].
Nonadherence is highly prevalent in patients with schizophre-
nia. Reviews of the literature report very divergent rates of
nonadherence, ranging from 20% up to 89% [113]. The overall rate
of nonadherence to antipsychotics is estimated roughly at 50%* Corresponding author. Tel.: +31 20 8913500; fax: +31 20 8913702.
E-mail address: e.barkhof@amc.uva.nl (E. Barkhof).
0924-9338/$ – see front matter  2011 Elsevier Masson SAS. All rights reserved.
doi:10.1016/j.eurpsy.2011.02.005[55]. The median rate of nonadherence during the ﬁrst two years
following a psychotic episode is 55% [30], and in ﬁrst episode
patients this leads to a ﬁve times higher chance of readmission
within a year [86].
This rate may even be an underestimation, as it does not
account for patients who refuse medication from the start or drop
out of follow-up studies [115].
The consequences of nonadherence can be devastating, for
patients and their families in terms of personal suffering,
hospitalization, reduced quality of life as well as for society in
general due to loss of income and direct costs of healthcare [109].
When looking at the problem of nonadherence, the divergent rates
reported in studies may partly reﬂect methodological obstacles.
One such obstacle concerns the difﬁculty to reliably measure
whether a patient is taking medication or not. In many studies,
self-report measures are used. In general, adherence self-reports
have proved to be unreliable, as they are likely to be inaccurate and
tend to overestimate actual levels of adherence [17,105]. Pill
counts are considered more reliable indicators of adherence, but
still offer no proof that the medication is actually taken. The
measuring of serum levels is a more direct method, but this often
forms an obstacle for patients who are reluctant to cooperate with
blood samples. Moreover, nonadherence is not an ‘all or nothing’
phenomenon. Partial adherence or changing adherence over time
E. Barkhof et al. / European Psychiatry 27 (2012) 9–1810frequently occurs. At ﬁrst glance partial adherence seems to be a
more limited problem compared to complete nonadherence.
Research, however, shows that even partial nonadherence is
associated with an increase in hospitalization rates and hence with
poorer outcomes, proportional to increasing days of nonadherence
[64,110].
This review aims at providing a comprehensive overview of the
available data on interventions designed to improve adherence to
medication in schizophrenia. Following an overview of the possible
causes of nonadherence, we will ﬁrst give a summary of the
research ﬁndings published before 2000, based on two previous
reviews [26,115]. Subsequently we will review the studies on
interventions for improving adherence to antipsychotic medica-
tion in patients with schizophrenia published between 2000 and
2009.
2. Factors inﬂuencing (non-) adherence
Why do patients stop taking their antipsychotic medication,
when there is clear evidence that in all likelihood doing so will
lead to an unfavorable outcome? On the other hand, one might ask
why patients do take their medication, as it appears to be difﬁcult
for anyone (including health care professionals themselves) to
adhere to a treatment, such as complying fully with the
completion of an antibiotic therapy, once the acute symptoms
of an infection have disappeared. The Health Belief model [5,78]
proposes that a person is willing to comply with a treatment when
one realizes that one’s health is at risk and one is ready to act on
that threat, and when the perceived beneﬁts of a proposed
treatment outweigh the costs of that treatment. For patients with
schizophrenia, there are several factors that may play an
important part in this intriguing process.
From a therapeutic perspective it is most interesting to focus on
modiﬁable factors inﬂuencing adherence to antipsychotic medi-
cation.
2.1. Illness awareness, insight into illness and general beliefs
Several studies and reviews report that patients with a low
degree of illness awareness and insight into their illness are more
likely to show poor adherence to treatment [1,30,55]. Also, general
beliefs and attitudes towards health and taking medication, based
on previous experiences, cultural factors and socioeconomic
status, are associated with adherence [56]. These factors might
contribute to the fact that the younger the age, the earlier the age of
onset of schizophrenia and the shorter the duration of illness, the
poorer the adherence rates are.
2.2. Psychopathology
Psychotic symptoms, especially paranoid and grandiose delu-
sions have been found to be negatively associated with adherence
[30], although not all studies on this issue show consistent results
[56]. Cognitive impairment as a cause for nonadherence yielded
inconsistent results in earlier studies [30], whereas more recent
research revealed that basic cognitive deﬁcits like attention and
memory deﬁcits are related to a patient’s difﬁculty in managing
medications [28,50]. Although negative symptoms intuitively
interfere with adequate adherence and are mentioned in the
literature in this respect [74], no data are as yet available to support
this hypothesis.
2.3. Medication related aspects
Efﬁcacy of antipsychotic medication is intricately related to
adherence. The antipsychotic effect reduces psychopathology,thereby improving adequate logic reasoning, required for insight
into illness. A good response to antipsychotic medication is
positively related to adherence, which is clearly demonstrated in
numerous studies. However, in the case of nonadherence, it seems
hard to determine whether lack of efﬁcacy of medication causes
nonadherence, or that nonadherence itself leads to persistence of
psychotic symptoms. In other words: is it the cause or the
consequence?
Another factor regarding medication and adherence are
medication side effects. Clearly, side effects are strongly and
negatively correlated to adherence. With the ﬁrst generation
antipsychotics especially extrapyramidal side effects are
reported [87,108], but also neuroleptic dysphoria may play a
role [23,102]. With the second-generation antipsychotics,
sedation and weight gain are associated with nonadherence
[76]. In studies comparing ﬁrst and second-generation anti-
psychotics, the latter show small advantages in tolerability and
relapse rates. However these advantages are not (directly)
associated with differences in adherence rates [61]. Therefore it
appears that in order to improve adherence, the choice of drug
should be dependent on the patient’s individual attitude and
response towards medication.
A third factor concerns the route of administration and dosing
strategies. On the one hand low dosing may result in fewer side
effects; however, very low doses may lead to sub-optimal efﬁcacy.
Reducing the dosing frequency to once-daily regimens has been
demonstrated to improve adherence rates [24,38]. The use of
depot medication has shown to be effective in preventing
nonadherence in studies with a follow-up of 1–7 years [85]. Also,
the one-year relapse rate for patients using depot medication was
signiﬁcantly reduced, compared to the relapse rate of patients
receiving oral medication [90]. Depot medication appears
particularly suitable to prevent covert nonadherence, as non-
adherence is directly noticeable by depot refusal and/or no-show
on physician appointments, which enables the treating physician
to act on this. Nevertheless, some studies show that even with
depot medication, nonadherence rates remain relatively high
[13,103]. Although randomized controlled data comparing
adherence to depot and oral antipsychotics are scarce due to
methodological problems, the available data have led to
recommendations in several guidelines for the use of depot
medication for patients with known recent medication non-
adherence [60].
2.4. Therapeutic alliance
It has been demonstrated that a good therapeutic alliance is
associated with better adherence rates [32]. Presumably related to
this, better adherence rates are also predicted by adequate
discharge planning and maintaining contact with outpatients
[56,66].
2.5. Environmental factors
Social support and in particular the support of family or
friends in assisting with medication taking, as well as stability of
living conditions, show some positive association with adher-
ence [30,56].
2.6. Substance abuse
Substance abuse is highly prevalent in patients with schizo-
phrenia and is strongly associated with nonadherence, leading to a
13-fold increased risk of patients with schizophrenia and
substance abuse to be non-adherent, in comparison with patients
who do not use substances [51].
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Table 1 shows the 47 studies published between 1980 and
1999, examined in two previous reviews covering interventions
to improve adherence to antipsychotic medication [26,115].
Though these two reviews are comparable in design and search
strategy, Dolder et al. [26] incorporated 21 studies, whereasTable 1
Studies 1980–1999.
Target of intervention Studies 
Individual interventions Randomized trials
Boczkowski et al. [8] 
MacPherson et al. [68] 
Streicker et al. [96] 
Frank and Gunderson [32] 
Hayward et al. [42] 
Kemp et al. [53,54] 
Group interventions Randomized trials
Malm et al. [69] 
Brown et al. [12] 
Eckman et al. [27] 
Atkinson et al. [2] 
Non-randomized trials
Seltzer et al. [91] 
Battle et al. [4] 
Family interventions Randomized trials
Strang et al. [95]; Falloon et al. [29] 
Leff et al. [57] 
Leff et al. [58,59] 
Tarrier [97] 
Glick et al. [34] 
Xiang et al. [111] 
Xiong et al. [112] 
Zhang et al. [114] 
McFarlane et al. [67] 
Razali and Yahya [83] 
Telles et al. [98] 
Schooler et al. [89] 
Razali et al. [84] 
Community interventions Randomized trials
Stein and Test [94] 
Bond et al. [9] 
Modrcin [73] 
Bush et al. [16] 
Ford et al. [31] 
Solomon and Drain [92] 
Non-Randomized trials
Bond et al. [10] 
Bigelow et al. [7] 
Bond et al. [11] 
Sands and Cnaan [88] 
Dixon et al. [25] 
Mixed-modality interventions Randomized trials
Hogarty et al. [44,45] 
Kelly and Scott [52] 
Guimon et al. [40] 
Herz [43] 
Linszen et al. [65] 
Hornung et al. [47,48]; Buchkremer et al. [1
Hogarty et al. [46] 
Azrin and Teichner [3] 
Merinder et al. [71] 
Adapted from: Zygmunt et al. [115]; Dolder et al. [26].Zygmunt et al. [115] incorporated 40 studies, using somewhat
broader criteria.
General conclusions were that interventions, which applied
only psychoeducational strategies without adjunctive components
such as family involvement or behavioural management, were
least successful in improving adherence to antipsychotic medica-
tion. Although psychoeducation did seem to enhance knowledgeResults
Behavioural training > Psychoeducation > TAU
3 sessions psychoeducation (PE) = 1 session PE = TAU
Psychoeducation = TAU
Psychotherapy focussing on therapeutic alliance > TAU
Medication self-management > TAU
Compliance therapy > non-speciﬁc counselling
Dynamic therapy = social skills training
Psychoeducation = TAU
Group behavioural intervention > TAU
Psychoeducation = waiting list
Psychoeducation > TAU
Psychoeducation (PE) daily = PE weekly = TAU
Behavioural management > intensive case management
Social interventions = TAU
Psychoeducation (PE) + family therapy = PE + relatives group
Behavioural enactive group = behavioural symbolic therapy =
psychoeducation = TAU
Family intervention = TAU
Psychoeducation > TAU
Psychoeducation + multiple family groups = TAU
Psychoeducation + multiple family groups = TAU
Multiple family psychoeducation (PE) = single family PE
Behavioural family therapy > TAU
Behavioural management = TAU
Supportive treatment = family management/problem solving
Behavioural intervention + medication > behavioural Intervention
Assertive community treatment > TAU
Assertive community treatment = TAU
Strengths case management = TAU
Assertive community treatment > TAU
Intensive case management > TAU
Intensive consumer case management = intensive case management
Assertive community treatment (ACT) + crisis house = ACT + purchased
house
Assertive community treatment = TAU
Assertive community treatment = educational supportive reference
groups = standard case management
Assertive community treatment > Intensive case management
Assertive community treatment > TAU
Family treatment + education = social skills training = family
treatment + social skills traning > TAU
In-home behavioural interventions = home and clinic
intervention > clinic intervention only = TAU
Patient + family group therapy > TAU
Individual + multifamily groups > TAU
Individual psychosocial + behavioural family intervention =
individual psychosocial intervention
4] Psychoeducation = psychoeducation + cognitive therapy =
psychoeducation + relatives group = psychoeducation + cognitive
therapy + relatives group = non-speciﬁc leisure-time group
Personal therapy = family psychoeducation = personal therapy +
family therapy = supportive therapy
Patient + family behavioural intervention = patient behavioural
intervention > psychoeducation
Family + patient Psychoeducation = TAU
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sufﬁcient to raise adherence rates.
Interventions using cognitive techniques directed at attitudes
towards medication showed favorable results, as well as beha-
vioural interventions. Family therapy programs showed no
considerable effect, unless they were accompanied by behavioural
components. The lack of effectiveness of family programs may in
part be accounted for by the fact that patients in family studies
already tended to be more adherent at baseline, probably because
of the family involvement, making it difﬁcult to detect an increase
in adherence. Interventions that were speciﬁcally designed to
improve adherence were more successful than programs that
intended to address a wider range of clinical problems, which
suggests that a more intensive and focused approach is required to
improve adherence rates. Here as well, a ceiling effect may play a
role, as most of the studies using speciﬁc interventions included
more non-adherent patients, allowing for a possibly greater
improvement.
The majority of studies that used an integrated approach,
combining several interventions to improve adherence, such as
cognitive behavioural techniques, family interventions and com-
munity based interventions, showed positive results.
Of the less speciﬁc intervention programs, which were not
exclusively designed to target adherence, assertive community
treatment and intensive case management seemed to be
positive exceptions, showing promising results in promoting
adherence.
Interventions with a greater number of therapeutic sessions
and a longer duration tended to produce greater improvement in
adherence to antipsychotic medication. Several studies with
negative results were relatively short in duration, which pleads
for more prolonged interventions or the use of booster sessions to
reinforce and consolidate gains made during short-term, more
intense interventions.
Several studies included only a limited number of participants.
Studies including more participants had a higher chance of
showing improvement in adherence rates, which suggests that
adequate sample sizes and thus sufﬁcient power are obviously
essential to determine the value of an intervention for improving
adherence.
4. Method
The review focuses on studies examining interventions to
improve adherence to antipsychotic medication in patients with
schizophrenia, published in English between 2000 and 2009. An
electronic search was conducted using Medline, PsychLIT, EMBASE
and CINAHL, with combinations of the keywords schizophrenia;
psychosis; adherence; compliance; intervention; therapy; program;
randomized; controlled; trial.
The selection criteria were as follows: (1) a randomized
controlled design, comparing a psychosocial intervention, at
least partially aimed at improving adherence with another
intervention or a control condition. A psychosocial intervention
is regarded a therapeutic intervention which is non-pharmaco-
logical in nature; (2) a sample of patients who were diagnosed
with a schizophrenia spectrum disorder; (3) a measure of
adherence to antipsychotic medication as a primary or second-
ary outcome. The search was supplemented by cross-
checking the references of the articles found in the electronic
search.
5. Results
Fifteen randomized controlled studies published between 2000
and 2009 met the inclusion criteria, as shown in Table 2.5.1. Individual interventions
In the last decade, seven adherence intervention studies
directed at the individual patient were performed, of which three
showed positive results. The purpose of four studies of these
studies was to investigate the effects of compliance therapy, while
trying to replicate earlier positive results by Kemp et al. [53,54].
Compliance therapy builds on cognitive behavioural therapy
combined with motivational interviewing [72]. A study by
O’Donnel et al. [77] failed to replicate the positive effect of
compliance therapy in a study with a similar design as the original
study by Kemp et al. [53,54]. Compliance therapy was slightly
modiﬁed into adherence therapy in one study [37], with a small
increase in the number of sessions (two extra sessions) and a more
individually tailored structure. This large European trial [37],
including 409 patients in four countries, did not ﬁnd any
differences between adherence therapy and a control group
receiving an individual intervention of health education, neither
where the primary outcome quality of life, nor where rates of
patient-reported medication adherence were concerned.
Another adaptation of compliance therapy is called adherence-
coping-education (ACE), which aims at enhancing insight and at
promoting treatment adherence in early psychosis patients. In a
pilot study [100] this intervention, consisting of 14 individual
sessions, was tested against supportive therapy. In a sample of 19
participants, perceived need for treatment and beneﬁts of
medication appeared to be better in patients with ACE shortly
after intervention, compared to controls. No direct adherence rates
were available and follow-up results are awaited.
Four studies focused on speciﬁc support for cognitive impair-
ments, based on the assumption that nonadherence in patients
with schizophrenia may be partly due to difﬁculties in e.g.
attention and memory. Reminders with SMS text messages in one
study [80] did not lead to better adherence, but a speciﬁc cognitive
adaptation training (CAT) did show positive results [106]. CAT uses
environmental supports such as signs, checklists, alarms and the
organizing of a patient’s belongings in order to cue and sequence
adaptive behavior. An extensive intervention (full-CAT) tackling
several aspects of functioning was compared with cognitive
adaptation focusing on medication only (Pharm-CAT) and with a
control group receiving treatment as usual, in a randomized trial
with 105 participants. The intervention was carried out for a period
of 9 months with a follow-up period of 6 months. It resulted in a
signiﬁcantly better adherence to medication for both intervention
groups, as measured by unannounced pill counts. Average
adherence rates were roughly 80% in the intervention groups
during the 15 months of the intervention and follow-up, compared
to 60% in the treatment as usual. The percentage of relapse for both
intervention groups was 35% against 81% for the control group.
This effect was maintained for 6 months after the intervention was
completed. Outcomes of social and occupational functioning
improved only with full-CAT, with a deterioration after the
intervention stopped, suggesting that these aspects probably ask
for continued intervention.
A relatively small study [6] reports a positive effect of a
telephone-nursing intervention (TIPS). This intervention com-
prises weekly calls by psychiatric nurses, trained to help patients
with problem solving, offering reminders and coping alternatives
with regard to common medication adherence barriers. Overall
adherence rates during the 3 months of the study were 80% in the
intervention group, versus 60,1% in the control group, as measured
in 3-monthly pill counts in an outpatient sample of 29 participants.
The fourth study to compensate for attention and memory
problems used a pharmacy-based intervention, called Meds-Help
intervention [101]. In a randomized controlled trial with 118
participants of which 67% had a schizophrenia spectrum disorder,
Table 2
Studies 2000–2009.
Intervention type Study Design Adherence measure Duration of intervention Follow-up
time
Adherence
outcome
Individual interventions Gray [35] n=44. Intervention group:
psychoeducation. Control group: TAU
Self-report 3 weekly sessions 2months Psychoeducation=TAU
O’Donnel et al. [77] n=56. Intervention group: compliance
therapy. Control group:
non-speciﬁc therapy
Self-, clinician- &
carer-report
5 weekly sessions 12months Compliance therapy=control
Gray et al. [37] n=409. Intervention group: adherence
therapy. Control group:
health education
Self-report 8 weekly sessions 12months Adherence therapy= control
Velligan et al. [106] n=95. Intervention group 1: full cognitive
adaptation training. Group 2:
partial cognitive adaptation training
(directed only at medication).
Control group: TAU
Unannounced pill
counts and
pharmacy records
39 weekly sessions 9+6months Full-CAT and Pharm-CAT>
TAU
Uzenoff et al. [100] n=24. Intervention group: adherence-
coping-education (ACE).
Control group: TAU
Self-report 6 weekly+8 biweekly
sessions
6months ACE>TAU on perceived need
for and beneﬁt of treatment
Peijnenborg et al. [80] n=62. Intervention group: SMS text
messages, with individualised
prompts. Control group: waiting list
Self-report Prompts during 7weeks 21weeks SMS group=waiting list on
adherence rates
Valenstein et al. [101] n=118. Intervention group: pharmacy-
based intervention. Control
group: TAU
Pharmacy records,
self-report
and blood test
12months 12months Pharmacy-based intervention>
TAU
Beebe et al. [6] n=29. Intervention group: telephone
intervention by nurses (TIPS)
directed at problem solving
Pill counts 3months 3months TIPS>TAU
Community interventions Gray et al. [36] n=72. Training of 52 nurses. Intervention
group: medication management
training. Control group: TAU
Self-report Unknown 6months Medication management>TAU
Hudson et al. [49] n=349. Training of nurses of 3 out of 6
VA networks. Intervention group:
guideline implementation and
patient-tailoring strategies. Control
group: TAU
Self-report and
medical record
>4 sessions in 6months 6months Enhanced strategy>TAU
Family interventions Ran et al. [82] n=326. Intervention group 1: family
psychoeducation+depot medication.
Intervention group 2: depot medication.
Control group: TAU
Clinician-report 9 monthly sessions +
3 multiple family workshops
9months Family psychoeducation +
depot>
depot-only>TAU
Li & Arthur [63] n=101. Intervention group: family
education. Control group: TAU
Self-report 36hours during admission+3
monthly sessions after
discharge
9months Family education=TAU on
adherence rates
Chan et al. [18] N=73. Intervention group: family
psychoeducation
Self-report 10 weekly sessions 12months Family psychoeducation>TAU
Mixed-modality
interventions
Petersen et al. [79] n=547. (OPUS trial) Intervention group:
integrated treatment (ACT+ family
involvement + social skills training.
Control group: TAU
Clinician-report 2-weekly multiple family
sessions for 18months+ social
skills training in
groups; unknown frequency
24months Integrated treatment>TAU
Morken et al. [75] n=50. Intervention group: integrated
treatment (intensive case management +
family psychoeducation + social skills
training+ individual cognitive behavioural
therapy
Self-report, controlled
by (not routinely)
clinician-report and
plasma levels
8 weekly family sessions +
22 monthly sessions + frequent
individual sessions,
on PRN-basis
24months Integrated treatment =TAU
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medication they were taking and a packaging education session;
reﬁll reminders were mailed 2 weeks before the scheduled reﬁll
dates. Also, clinicians received notiﬁcation when a patient failed to
collect his antipsychotic prescriptions. Statistically signiﬁcant
improvements in medication possession rates (MPR) were
observed in the intervention group after 6 and 12 months,
compared with a control group that received care as usual. When
a more stringent measure of adherence was used, by combination
of a MPR of greater than 80% with a positive subjective assessment
of adherence and a blood test indicating the presence of some
antipsychotics, 50% of the intervention group fulﬁlled the criteria
of adherence after 6 months versus 17% in the control group.
5.2. Family interventions
After 2000, four studies were carried out using family
interventions, all conducted in China. One study [19] provides
no data on actual adherence rates. Of the three remaining studies,
two showed positive results on adherence to medication. In a rural
area in China, Ran et al. [82] carried out a cluster randomized trial
with 357 participants, in which three groups were compared. Both
intervention groups received depot medication. One intervention
group received in addition a monthly psychoeducational family
intervention, in which patients were encouraged to participate, 3-
monthly multiple family sessions and crisis family interventions
when necessary. After 9 months, 35% of patients in the combined
treatment group maintained regular treatment, in comparison
with 32% in the depot-only group and 5% in the control group. The
numbers of patients who did not comply with treatment at all were
2% in the combined group, 27% in the depot group and 50% in the
control group, with accordingly increasing rates of relapse.
Chan et al. [18] investigated a psychoeducational program for
patients and their family caregivers in the urban area of Hong
Kong. Seventy-three patients were included and the intervention
consisted of 10 family sessions of psychoeducation within a period
of 3 months, which was compared with routine care. One month
after completion of the interventions, and again 6 months later,
signiﬁcant differences in favor of the intervention group were
reported on adherence to medication, as measured by the Rating Of
Medication Inﬂuences scale (ROMI), yet these were not sustained
after 12 months of follow-up. The same effect was found for illness
insight. Also, family burden and self-efﬁcacy on the part of the
family initially ameliorated, but this effect was not sustained after
12$months either.
5.3. Community interventions
Two studies in the last decade focused speciﬁcally on training of
psychiatric nurses. Gray et al. [36] examined in a randomized
controlled cluster trial a medication management training package
for Community Mental Health Nurses. Half of the 52 participating
nurses received the training package, consisting of side effects
management as well as training in effective treatment strategies
for schizophrenia. The other half of the group of nurses received no
training and delivered treatment as usual. At the follow-up after
12 months, 29 patients treated by the trained nurses improved
signiﬁcantly in adherence rates, on a clinician rating scale as used
in the study by Kemp et al. [53] and on patient attitudes towards
medication, as well as on symptomatology, compared with a group
of 24 patients receiving care from the non-trained nurses.
In a comparable study [49] six US Department of Veteran Affairs
medical centers received basic guideline implementation strate-
gies for the treatment of schizophrenia. Three of the six medical
centers received an enhanced implementation strategy, in which
physicians were trained to prescribe guideline-concordant. Inaddition, a research nurse identiﬁed barriers of adherence in
patients. The nurses were trained in a protocol designed to assess
medication adherence, strategies to maintain contact with the
patients and provide feedback to the physician about adherence
(barriers) and treatment preferences. Patients enrolled at the sites
receiving the enhanced intervention, appeared almost twice as
likely to be adherent at the follow-up after 6 months, as measured
by patient report and chart reviews.
5.4. Mixed-modality interventions
Two studies examined integrated treatments, one of which
showed a positive result. This regards the Danish OPUS trial [79], a
large randomized clinical trial for ﬁrst episode psychosis patients.
The study investigated an integrated treatment, encompassing
assertive community treatment, family involvement and social
skills training and compared it to treatment as usual. Adherence
was only indirectly measured by participation in the treatment
program, which showed signiﬁcant differences after a follow-up of
one year. Discontinuation of treatment for more than a month
occurred in 8% of patients in the intervention group, against 22% in
the control group. The percentage of patients stopping treatment
in spite of necessity was 3% versus 15% in the control group, and the
number of patients not making any outpatient visits 4% versus 15%.
At a two-year follow-up, these differences were smaller and no
longer signiﬁcant for the groups stopping treatment or those
discontinuing treatment for more than a month. In the interven-
tion group also positive and negative symptomatology as well as
substance abuse outcomes were signiﬁcantly more favorable
compared to treatment as usual; these results were maintained at
two years follow-up.
6. Discussion
From the studies between 1980 and 1999 can be concluded that
psychoeducational interventions show little effect on adherence,
unless they are accompanied by behavioural and cognitive
interventions that aim directly at medication attitudes and
adherence behaviour. In general, combined interventions and a
longer duration of interventions were associated with favorable
outcomes.
Compliance therapy, consisting of a combination of motiva-
tional interviewing and cognitive behavioural therapy, raised high
expectations, as it appeared an effective strategy in a clinical
population and maintained a superior effect over supportive
therapy after 18 months [53,54].
In the period after 2000, 16 studies were published that met the
inclusion criteria of this review. Three studies [37,70,77] elaborat-
ed on the apparent success of compliance therapy, but the
expectations have not yet been fulﬁlled. A direct replication of the
study by Kemp et al. [53,54], using the same intervention and a
similar study population, was undertaken by O’Donnell et al. [77],
yielding no difference in adherence rates between four to six
sessions of compliance therapy and a control condition. Practically
the same intervention, with an extended duration of six to eight
sessions, renamed adherence therapy because of the negative
connotation of the word compliance, was tested in a large
European multicenter study [37], but yielded no differences either
on adherence rates after one year. Only a small study in Thailand
[70] found a modest effect of Adherence Therapy, but was not
included in this review, as no direct adherence measures were
applied. A possible explanation for these overall negative ﬁndings
might be that the initial adherence rates of participants in these
studies were moderate, leaving less room for amelioration,
although even a subgroup with low adherence rates at baseline
in the study by Gray et al. [37] did not seem to beneﬁt from the
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inﬂuence was the fact that the intervention was given during a
relative short period by a therapist who was not a member of the
treating staff, which might have diluted the actual effect.
Supporting this assumption, the two studies focusing on
training case-managers (nurses) in medication management
[36] and patient-tailoring strategies and guideline implementation
[49], did show positive results on medication adherence in the
patients they treated. An evaluation of a medication management
training program for community mental health professionals [41],
not included in this review as it used no direct measure of
adherence, found a positive effect on service user involvement in
treatment. These ﬁndings might indicate how important the
continuation of managing of adherence issues is, or how important
it is that interventions aimed at promoting adherence are
undertaken by the actual treating caregiver, though it is likely
that a combination of these is essential.
With regard to the duration of the intervention, Uzenoff et al.
[100] showed in a preliminary trial that expanding the number of
interventions of adherence therapy over a longer period of time,
combined with a focus on coping strategies called adherence-
coping-education therapy, leads to favorable outcomes in patients
following a ﬁrst psychotic episode. The timing of the intervention
may also play an important role and might therefore account for
certain differences in effect of the interventions. However, timing
of the intervention could not be identiﬁed as a predictor for
success from our review. Some studies [49,79] only offered the
intervention early on in the treatment after a relapse, thus with
subjects in an instable phase of their disorder, whereas other
studies also included more stabilized patients [18,37,100]. This
may, however, turn both ways; relatively stable patients will be
more capable to beneﬁt of certain psychosocial interventions,
while on the other hand the baseline adherence levels in such a
group are generally higher, with less opportunity for improve-
ment of adherence levels.
Also, in the past decade attention was given to compensation
for cognitive deﬁcits in patients with schizophrenia, using
environmental supports such as checklists, signs and electronic
cuing devices. From the four studies included in this review,
reminders with SMS text messaging to support medication taking
[80] did not lead to better adherence, but a telephone intervention
by nurses [6] and especially Cognitive Adaptation Training [106]
did show promising results, as well as a pharmacy-based
intervention [101]. Supporting patients in collecting their antipsy-
chotic prescriptions and behavioural techniques to facilitate taking
medication clearly have a positive inﬂuence on adherence
behavior. This is in agreement with ﬁndings in studies regarding
patients suffering from other chronic medical disorders [21], who
have comparable nonadherence rates. This suggests that all
patients with chronic conditions and poor adherence could beneﬁt
from reducing access barriers by the use of pharmacy-based
interventions and concrete problem-solving interventions accom-
panied by technical aids. Whether this effect is irrespective of the
underlying nature of the disease remains an open question, but it
sheds an interesting light on the causes of nonadherence in
schizophrenia spectrum disorders. It could be hypothesized that if
patients with other chronic conditions beneﬁt from these
supportive measures, patients with schizophrenia in particular
are in need of these measures, as cognitive problems are highly
prevalent in schizophrenia.
Another initiative involving communication technology, not
included in this review, aims at detecting prodromal symptoms of
relapse; it uses a short questionnaire for patients and caregivers by
a weekly SMS text message to make an early intervention possible.
It shows promising results in an open study [93], but needs to be
tested in a randomized controlled trial.In line with the ﬁndings in the studies before 2000, studies in
the past decade that offered more sessions during a longer period
of time were more likely to be successful. Possibly due to the
prolonged duration of interventions, in the past decade family
interventions showed positive results, unlike the studies before
2000.
Of the interventions whose purpose it was not only to raise
adherence in the individual patient, but encompassed other
treatment targets as well, both the two community interventions,
two out of three family interventions and one of the two mixed-
modality interventions showed positive results, which suggests
that a wider range of targets may be needed to promote adherence
to medication, such as resuming rewarding life roles and regaining
functional capacities. Given the fact that impaired illness insight is
an important contributing factor to nonadherence, the wider range
of targets possibly explains why, even when insight is not
ameliorated, these comprehensive interventions may be of beneﬁt,
as they link medication adherence to the achievement of functional
goals. However, the variety in targets and outcome variables in
these studies, make it difﬁcult to deﬁne what components are
speciﬁcally relevant to raise adherence rates for patients with
schizophrenia, and whether there are subgroups of patients who
need different approaches in dealing with adherence problems.
Further elaborating on this, a recent expert consensus guideline
[107] proposes the use of strategies targeted at speciﬁc types of
adherence problems, thereby developing an individually tailored
approach to promote adherence. This appears to be a promising
direction, which will require regular updates and input of ongoing
initiatives to more elaborately specify the relevance of speciﬁc
interventions for speciﬁc problems and for certain subgroups of
patients.
It means that there is a great demand for more studies on this
multifaceted problem, especially considering the methodological
problems researchers face when measuring the effectiveness of
adherence interventions, given the heterogeneity of the population
and the large number of possible inﬂuencing factors. This calls for
large well-powered studies targeting speciﬁc interventions.
Yet another interesting approach is offered in an outline by
Priebe et al. [81], who are currently undertaking a study to
investigate the effect of a ﬁnancial incentive to raise adherence
rates. Inspired by the positive effect of ﬁnancial incentives in
patients with substance abuse, an earlier small open label study in
the UK [20] in assertive outreach teams showed an amelioration of
medication adherence in four out of ﬁve patients, in a mixed
population with mental health problems and substance abuse. The
use of ﬁnancial incentives raises some ethical considerations
because of the risk of ﬁnancial dependency, increasing ﬁnancial
demands and/or extortion [81]. However, ﬁnancial incentives have
proven earlier to be successful in other medical areas, such as
enhancing adherence to medication for tuberculosis and hyper-
tension, as well as adherence to dental care or a weight
management program [39].
There are some limitations to interpretation of the studies
included in this review. As mentioned earlier, a number of the
interventions were not speciﬁcally designed to improve only
adherence, but also to address a wider range of targets and
subsequent outcome variables. This makes it difﬁcult to determine
which components are essential to improve adherence rates in
these studies. Furthermore, the included studies are heteroge-
neous in design and in the adherence measures that were used,
which makes it difﬁcult to compare the outcomes and draw
general conclusions. Another limitation is the publication bias. In
pharmacological studies [99], negative results are less likely to be
published than positive results. This may also be the case here and
may lead to overestimation of certain effects. Finally, measuring
adherence, in particular in patients with schizophrenia, remains
E. Barkhof et al. / European Psychiatry 27 (2012) 9–1816very challenging. It is clear that indirect or subjective measures of
adherence (self-report, clinician-report, caregiver-report) are less
reliable than direct or objective measures (such as pill counts,
electronic devices (MEMS), electronic reﬁll records, assays of
medication levels in blood or urine samples). Subjective reports
systematically tend to overestimate adherence [104]. In order to
include a representative patient population, the wish for accuracy
on this matter, for research purposes, must be outweighed against
the apparent reluctance to cooperate with more ‘invasive’ research
measures (such as blood samples) in patients with schizophrenia
and adherence problems.
All the same, some conclusions can be drawn from this review.
Firstly, interventions that are longer in duration and offer more
sessions, and especially interventions that provide continuous
focus on adherence, tend to be more successful at improving
adherence than interventions of short duration. Secondly, the use
of problem-solving interventions accompanied by technical aids,
including pharmacy-based interventions, is clearly promising;
they appear to ameliorate adherence in all chronic conditions,
including schizophrenia. Thirdly, the positive effects of adapted
forms of motivational interviewing found in earlier studies, such as
compliance therapy, have not yet been conﬁrmed. Finally, it
appears that the heterogeneity of factors related to nonadherence
calls for individually tailored approaches to promote adherence.
As it is recognized that nonadherence contributes enormously
to poor outcome, substantial work needs still to be done.
Acknowledging that the problem has to be dealt with on a
structural and consistent basis is the ﬁrst step. More evidence and
exploration of the validity and effectiveness of speciﬁc interven-
tions aimed at improving adherence is required to raise the
standard of care and clinical outcome for patients with schizo-
phrenia.
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